Ocean Biomedical faces Nasdaq delisting over late Q3 2024 10-Q; hearing Dec 16

Ocean Biomedical, Inc.

Received Nasdaq notice on Nov 18, 2024 for failure to file Form 10-Q for period ended Sep 30, 2024.
This is an additional basis for delisting; prior delinquencies include 2023 10-K and Q1/Q2 2024 10-Qs.
Nasdaq Hearings Panel will consider the matter at hearing scheduled for December 16, 2024.
Company intends to file delinquent reports as soon as practicable; no immediate effect on trading.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.